The Food and Drug Administration on Friday approved Eli Lilly’s anti-obesity drug Zepbound as the first prescription medicine ...

Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...

Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f ...

and obesity. “Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” Dr. Sally Seymour, director of the Division of Pulmonology ...

The FDA’s decision makes Zepbound the first approved drug treatment for patients with obesity and moderate-to-severe obstructive sleep apnea, or OSA. “Too often, OSA is brushed off as ‘just ...

Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity ... they pay.Zepbound is FDA-approved to treat obesity and Mounjaro is ...

If coverage is structured properly, it could greatly help our country's chronic disease and obesity epidemics. But Donald Trump's Food and Drug Administration (FDA) will also need to ensure the drugs ...

The Food and Drug Administration on Friday approved Eli Lilly’s anti-obesity drug Zepbound as the first prescription medicine for obstructive sleep apnea, marking a major shift in the treatment ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss ... likely opens the door to Medicare coverage of an anti-obesity medication a bit wider than when the FDA approved ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight-loss drug Zepbound. The medicine, part of the class known as GLP-1 ...